AbbVie signs cancer drug development deal with up to $2.5B in milestones
North Chicago, Ill.-based AbbVie has entered a collaboration and option-to-license agreement with Cologne, Germany-based DISCO Pharmaceuticals to develop cancer therapies targeting solid tumors, DISCO announced Nov. 19. Under the agreement, DISCO will receive $40 million upfront and is eligible for up to $2.5 billion in option, development and other milestone payments, plus tiered royalties on […] The post AbbVie signs cancer drug development deal with up to $2.5B in milestones appeared fi...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.